Efficacy and safety of early initiation of anticoagulant therapy in patients with atrial fibrillation and asymptomatic hemorrhage transformation after infarction

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064319

Enrollment

Unknown

Registered

2022-10-02

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Early anticoagulation group:Early anticoagulation

Conrol group:Oral Savariban 2 weeks after stroke

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for acute cerebral infarction (onset = 18 years; 4. Scores of modified Rankin scale <= 2 before onset; 5. The bleeding transformation was according to the ECASS classification criteria and met the HI manifestations; 6. The clinical symptoms were not significantly aggravated, and the NIHSS score increased by less than 4 points; 7. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Valvular heart disease; 2. Clinically active bleeding or risk of major bleeding; 3. Previous hemorrhagic cerebrovascular disease; 4. Coagulopathy and thrombocytopenia; 5. Renal insufficiency, creatinine clearance <50mL/min; 6. The stroke underwent endovascular treatment; 7. Life expectancy less than 30 days; 8. Patients who cannot adhere to oral rivaroxaban.

Design outcomes

Primary

Measure	Time frame
Recurrence of cerebral ischemic events;	—

Countries

China

Contacts

Public ContactWang Yueheng

Dujiangyan People's Hospital

554220166@qq.com+86 1803713878

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026